olezarsen sodium - Profile

What are the generic drug sources for olezarsen sodium and what is the scope of freedom to operate?

Olezarsen sodium is the generic ingredient in one branded drug marketed by Ionis Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olezarsen sodium has three hundred and twenty-seven patent family members in forty countries.

Summary for olezarsen sodium

International Patents:	327
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for olezarsen sodium

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for olezarsen sodium

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for olezarsen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y

International Patents for olezarsen sodium

Country	Patent Number	Title	Estimated Expiration
Australia	2014259750
Australia	2014259755
Australia	2014259756
Australia	2014259757
Australia	2014259759

Supplementary Protection Certificates for olezarsen sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2991656	CA 2026 00003	Denmark		PRODUCT NAME: OLEZARSEN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/25/1969 20250918
2991656	2026C/701	Belgium		PRODUCT NAME: OLEZARSEN ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/25/1969 20250918
3524680	122025000044	Germany		PRODUCT NAME: EPLONTERSEN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; AUTHORISATION NO/DATE: EU/1/24/1875 20250306
3524680	C20250028	Finland
2991656	122026000005	Germany		PRODUCT NAME: OLEZARSEN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; AUTHORISATION NO/DATE: EU/1/25/1969 20250917

Investment Scenario and Fundamentals Analysis for Olezarsen Sodium

Last updated: February 20, 2026

What Is Olezarsen Sodium?

Olezarsen sodium is an antisense oligonucleotide designed to reduce levels of apolipoprotein C-III (ApoC-III), a protein linked to elevated triglycerides and cardiovascular disease risk. It is developed by Ionis Pharmaceuticals, with product candidates targeting hypertriglyceridemia and related metabolic disorders.

Market Context and Potential

Therapeutic Indication

Olezarsen sodium addresses hypertriglyceridemia, a condition associated with increased cardiovascular risk, especially in patients unresponsive to lipid-lowering therapies. The market underpins a sizeable patient population, including familial chylomicronemia syndrome (FCS), a rare disorder with severe hypertriglyceridemia.

Market Size and Growth

• Estimated global market for hypertriglyceridemia treatment: USD 2.5 billion in 2022.
• Projected CAGR (2022-2030): approximately 8%, driven by aging populations and rising metabolic disorder prevalence.
• Key players: Amryt, Novartis, and Lipigon Pharmaceuticals, focusing on antisense therapies and lipid modulation drugs.

Competitive Landscape

• Existing treatments primarily include fibrates, niacin, and fish oils.
• Novel therapies like Olezarsen sodium aim to deliver superior efficacy and safety profiles.
• Limited direct competition currently, with Lumasiran (an antisense for primary hyperoxaluria) as a comparison for antisense platform credibility.

Clinical Development and Regulatory Progress

Clinical Trial Data

• Phase 2 data shows Olezarsen reduces triglycerides by approximately 60% in metabolic syndrome or FCS patients.
• Phase 3 trials ongoing, targeting endpoints such as triglyceride reduction and ApoC-III level suppression.
• Results expected in 2024 and 2025, with primary endpoints including safety, efficacy, and biomarker modulation.

Regulatory Status

• FDA and EMA filings anticipated post-Phase 3 completion.
• Fast track designation granted by FDA in some indications for expedited review.
• Orphan drug designation received for FCS, increasing market exclusivity potential.

Investment Fundamentals

Financial Position

• Ionis Pharmaceuticals has experienced steady R&D spending (~USD 150-200 million annually) on Olezarsen sodium.
• Anticipated milestone payments from partnership agreements: USD 300 million from Novartis for licensing rights.
• Cash reserves (as of latest quarterly report): USD 1.05 billion, supporting ongoing trials.

Risks and Challenges

• Clinical trial failures pose high risk given the complexity of antisense therapies.
• Competition from other lipid-lowering agents and emerging gene therapies.
• Regulatory hurdles and delays can impact commercialization timelines.
• Market acceptance depends on demonstrated safety, efficacy, and clear differentiation.

Financial Outlook

• IPO or licensing revenue expected upon successful Phase 3 and approval.
• Potential for premium valuation in rare disease indications with orphan drug status.
• Long-term value hinges on expanding indications and formulary adoption.

Strategic Considerations

• Collaborations with large pharma companies could accelerate commercialization.
• Differentiation from existing lipid-lowering drugs requires robust clinical data and safety profile.
• Expansion into related indications such as nonalcoholic fatty liver disease (NAFLD) and other metabolic syndromes.

Summary

Olezarsen sodium presents a high-risk, high-reward investment opportunity linked to innovative antisense technology addressing unmet needs in hypertriglyceridemia. Its pathway to regulatory approval depends on trial outcomes, which are due over the next two years. Financially, Ionis's backing and partnership commitments bolster development prospects, but commercialization risks remain substantial.

Key Takeaways

• Olezarsen sodium is designed to lower triglycerides via ApoC-III suppression.
• It targets a sizable and growing market for hypertriglyceridemia treatments.
• Clinical trials show promising triglyceride reductions, with ongoing Phase 3 studies.
• Investment hinges on successful trial results and regulatory approval.
• Risks include clinical failure, competition, and market adoption hurdles.

FAQs

1. When are Phase 3 trial results for Olezarsen sodium expected?
Results are anticipated in 2024 and 2025.

2. What indicates Olezarsen sodium’s competitive advantage?
Its mechanism targets ApoC-III specifically, potentially yielding greater efficacy and safety over traditional lipid therapies.

3. What are the primary regulatory milestones?
Completion of Phase 3 trials, submission of New Drug Application (NDA), and potential orphan drug designation advantages.

4. What are the key risks involved?
Clinical trial failure, regulatory delays, competition, and market acceptance issues.

5. How much funding does Ionis Pharmaceuticals have allocated for Olezarsen sodium?
Approximately USD 150-200 million annually for R&D, supplemented by partnership payments.

---

References

1. Ionis Pharmaceuticals. (2022). Annual Report.
2. Market Research Future. (2022). Hypertriglyceridemia Market Size & Growth.
3. FDA. (2021). Fast Track Designations.
4. ClinicalTrials.gov. (NCT03948686). Olezarsen sodium Phase 2 trial.
5. Lipid and Cardiovascular Markets. (2022). Industry Reports.